Orthocell Ltd (ASX: OCC) shares are starting the month on a positive note.
In morning trade, the ASX All Ords stock is up 7% to $1.26.
Why is this ASX All Ords stock jumping?
The catalyst for today's gain has been the release of a sales update from the regenerative medicine company.
According to the release, the ASX All Ords stock delivered record revenue of $2.73 million for the fourth quarter ended 30 June 2025. This represents a 22.8% on the previous record of $2.22 million in the March 2025 quarter.
Impressively, this revenue result was achieved prior to any contribution from its Remplir product in the United States. Sales in this key market are expected to ramp up during the first half of FY 2026, which management believes underscores its commercial momentum and growing penetration in existing markets of the flagship nerve repair product.
Remplir is a collagen wrap used in nerve repair surgery to assist surgeons to improve outcomes in the repair and regeneration of damaged nerves.
What was the driver of this strong result?
The driver of its record result was strong demand for Remplir in Australia. Management believes this reflects continued traction with surgeons due to "the superior, consistent and predictable outcomes surgeons can achieve using Orthocell's products."
It highlights that Remplir is now being used by over 200 surgeons across over 165 hospitals and continues to consistently grow.
This number could increase significantly in the next 12 months. With US FDA approval and a network of 14 specialist nerve distributors in the US market, management is very optimistic on its prospects. It notes that it "anticipates that US sales will gather pace in the coming months as more surgeons and healthcare professionals gain familiarity with Remplir."
The ASX All Ords stock's CEO and managing director, Paul Anderson, was rightfully pleased with the quarter. He said:
Achieving a record of $2.73 million in revenue for the June quarter reflects the continued strong market response to our market leading products Striate and Remplir. This outstanding result is driven by growing demand from surgeons in our existing markets and lays a solid foundation for our US expansion which we expect to ramp up in the first half of FY26.
We're seeing our commercialisation strategy in Australia starting to bear fruit and we are confident this will be replicated on a much larger scale in the US. With our highly experienced US distributors appointed and our first surgical use completed after achieving FDA clearance, we are well-positioned to accelerate growth in the US$1.6 billion nerve repair market over the coming months.
